Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, and is one of the most important targets for biological therapy, especially for non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). In the past 15 years, several EGFR antagonis...

Full description

Bibliographic Details
Main Authors: Troiani, Teresa, Napolitano, Stefania, Della Corte, Carminia Maria, Martini, Giulia, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Fortunato
Format: Online
Language:English
Published: BMJ Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070253/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070253/

Similar Items